Japan's drug firms on the move
A homespun elixir
With growth limited at home, Japan’s pharma industry is buying firms abroad
May 20th 2010 | TOKYO
Beta v1.3
Advertisement
Most commented
- Skopje: A Macedonian makeover
- Science and religion: Another ungodly squabble
- An immigration row in Germany: Sarrazin vs the Saracens
- Europe's economies: Turbocharged Germany
- Banyan: Afloat on a Chinese tide
- Burning the Koran: Religious extremist tag-team stunts
- The United States and Latin America: Nobody's backyard
- Putin in Valdai: Vladimir Putin's Valdai vision
- India's disappointing government: Much less than promised
- ETA calls a ceasefire: An uninspiring truce
Over the past five days
Most recommended
- Science and religion: Another ungodly squabble
- The future of the internet: A virtual counter-revolution
- India's disappointing government: Much less than promised
- Maids in the Middle East: Little better than slavery
- Higher education and wages: Study leave
- An immigration row in Germany: Sarrazin vs the Saracens
- The United States and Latin America: Nobody's backyard
- Sexual selection: Lord of the dance
- Schumpeter: Declining by degree
- KAL's cartoon
Over the past seven days
Advertisement
Products & events
Stay informed today and every day
Subscribe to The Economist's free e-mail newsletters and alerts.
Subscribe to The Economist's latest article postings on Twitter
See a selection of The Economist's articles, events, topical videos and debates on Facebook.
Advertisement
Readers' comments
Sort:
Just a correction: the mandatory price cuts are not biannual (twice a year) as you wrote, but biennial (every two years).
I am not usually pedantic but this difference is rather important for pharma in Japan.
Pelle Stolt
Ranbaxy is a good company, gave gr8 stock returns. Good for Daichi Sankyo and other Japanese firms, way to go!